Sirolimus 0.5 mg
CT2-02-17
Phase 2 small_molecule active
Quick answer
Sirolimus 0.5 mg for Beta-Thalassemia is a Phase 2 program (small_molecule) at Ultragenyx UK Limited with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx UK Limited
- Indication
- Beta-Thalassemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active